Skip to main content

Table 1 The drugs significantly associated (FDR < 0.1) with the network-signature classification based on CMAP analysis

From: A network model for angiogenesis in ovarian cancer

Drug name

CMAP rank

CMAP P-value

CMAP FDR

Network signature

Expression signature

Network signature

Expression signature

Network signature

Expression signature

Harmol

1

61

4.6E-04

1.1 × 10−3

0.015

4.9 × 10−3

Harmalol

2

67

4.9E-04

1.8 × 10−3

0.015

7.1 × 10−3

Brinzolamide

3

95

5.6E-04

5.8 × 10−3

0.016

0.020

Edrophonium chloride

4

42

6.0E-04

3.6 × 10−4

0.017

1.8 × 10−3

Trimethadione

5

138

6.8E-04

0.035

0.018

0.101

Canavanine

6

39

7.0E-04

2.7 × 10−4

0.018

1.5 × 10−3

Oxamniquine

7

49

1.3E-03

6.0 × 10−4

0.025

2.8 × 10−3

Metolazone

8

59

1.3E-03

1.0 × 10−3

0.025

4.4 × 10−3

Etofylline

9

112

3.2E-03

0.015

0.048

0.048

Harmine**

10

613

3.6E-03

1.000

0.051

1.000

Tetracycline

11

108

4.0E-03

0.013

0.056

0.041

Sotalol

12

136

5.5E-03

0.033

0.069

0.096

5213008

13

55

6.5E-03

8.1 × 10−4

0.080

3.7 × 10−3

Prestwick-675

14

1

7.3E-03

6.0 × 10−6

0.084

5.2 × 10−5

Pirinixic acid

15

21

8.6E-03

2.4 × 10−5

0.095

1.8 × 10−4

Dicoumarol**

16

184

8.8E-03

0.239

0.097

0.534

Pentoxyverine**

17

784

9.1E-03

1.000

0.098

1.000

Adipiodone**

18

689

0.010

1.000

0.100

1.000

  1. Drugs that are not significantly associated with the expression-signature are bolded and asterisked (**).